Aristo Bio-Tech & Lifescience
Aristo Bio-Tech & Lifescience (ARISTO) share price was ₹86.00 at the 26 Oct 2026 close; market capitalisation ₹58.55 Cr; sector Chemicals. The share price fell 33.9% over the year to 26 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue rose 2.9% year on year to ₹107 Cr and net profit was ₹3 Cr, against under ₹1 Cr a year earlier (compared with Mar 2025). Promoters held 73.42% of Aristo Bio-Tech & Lifescience in Sep 2026, unchanged from Mar 2026.
Key Fundamentals
SMEFertilizers & AgrochemicalsChemicalsPrice-based figures as of 26 Oct 2026, 15:30 IST · TTM
Peer Comparison
Commodities › Chemicals › Pesticides & Agrochemicals
| ₹540.75 | 22.58 | 45,648 Cr | 1.32 | 1.16% | 5.38% | 10.85% | 53,683 Cr | 2,323 Cr | |
| ₹2,103.80 | 27.39 | 31,918 Cr | 2.84 | 0.72% | 11.76% | 14.68% | 6,914 Cr | 1,164 Cr | |
| ₹333.55 | 28.70 | 16,649 Cr | 4.50 | 0.38% | 16.00% | 20.98% | 3,409 Cr | 581 Cr | |
| ₹3,291.00 | 20.20 | 14,790 Cr | 4.99 | 4.59% | 23.24% | 27.93% | 5,761 Cr | 733 Cr | |
| ₹692.75 | 9.98 | 6,250 Cr | 1.99 | 2.31% | 21.71% | 25.26% | 5,464 Cr | 626 Cr | |
| ₹884.95 | 14.86 | 3,945 Cr | 2.35 | 0.23% | 21.17% | 27.37% | 2,071 Cr | 268 Cr | |
| ₹188.28 | 17.10 | 3,661 Cr | 1.67 | 1.58% | 9.68% | 12.75% | 2,631 Cr | 214 Cr | |
| ₹86.00 | — | 59 Cr | 1.33 | 0.70% | 16.29% | 26.25% | — | — | |
| Median 8 companies | ₹616.75 | 20.20 | 10,520 Cr | 2.17 | 0.94% | 16.15% | 23.12% | 5,464 Cr | 626 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Strengths
1- Company has delivered good profit growth of 46.1% CAGR over last 5 years
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 8% · Mar 2026
Quarterly Results
| Particulars | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 73 | 129 | 89 | 133 | 112 | 214 | 104 | 256 | 107 |
| Expenses | 72 | 124 | 85 | 128 | 109 | 206 | 103 | 249 | 99 |
| Operating Profit | 1 | 5 | 4 | 5 | 3 | 8 | 1 | 8 | 8 |
| OPM % | 1.2% | 3.9% | 4.1% | 4% | 2.9% | 3.8% | 1.1% | 3.1% | 8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | -1 | 4 | 1 | 4 | 2 | 6 | -1 | 6 | 4 |
| Tax % | -35% | 28% | 13% | 28% | 27% | 25% | -18% | 25% | 27% |
| Net Profit | 0 | 3 | 1 | 3 | 1 | 5 | 0 | 4 | 3 |
| EPS (₹) | -0.48 | 3.8 | 1.47 | 3.78 | 1.94 | 6.68 | -0.72 | 6.13 | 4.42 |
Profit & Loss
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57 | 159 | 271 | 202 | 201 | 167 | 166 | 218 | 245 | 318 | 364 |
| Expenses | 56 | 157 | 263 | 195 | 197 | 163 | 160 | 209 | 236 | 309 | 348 |
| Operating Profit | 1 | 3 | 7 | 7 | 5 | 4 | 5 | 9 | 8 | 9 | 16 |
| OPM % | 1.6% | 1.6% | 2.7% | 3.4% | 2.2% | 2.6% | 3.3% | 4% | 3.5% | 2.9% | 4.4% |
| Other Income | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 1 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 4 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 |
| PBT | 1 | 3 | 6 | 4 | 1 | 2 | 2 | 5 | 5 | 5 | 10 |
| Tax % | 33% | 31% | 34% | 31% | 28% | 28% | 28% | 25% | 28% | 26% | 26% |
| Net Profit | 0 | 2 | 4 | 3 | 1 | 1 | 1 | 4 | 4 | 4 | 7 |
| EPS (₹) | 0.8 | 3.7 | 7.48 | 5.67 | 2.02 | 2.16 | 2.14 | 5.23 | 5.73 | 5.96 | 10.55 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 7% | 10% | 6% |
Balance Sheet
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 5 | 5 | 5 | 7 | 7 | 7 | 7 |
| Reserves | 2 | 4 | 7 | 6 | 7 | 8 | 10 | 23 | 27 | 31 | 37 |
| Borrowings | 5 | 10 | 20 | 14 | 20 | 22 | 25 | 22 | 21 | 22 | 35 |
| Other Liabilities | 20 | 72 | 60 | 65 | 56 | 46 | 37 | 47 | 73 | 81 | 76 |
| Total Liabilities | 27 | 87 | 89 | 91 | 88 | 81 | 77 | 100 | 127 | 141 | 155 |
| Fixed Assets | 2 | 2 | 8 | 8 | 8 | 12 | 14 | 16 | 22 | 24 | 24 |
| CWIP | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 25 | 85 | 81 | 81 | 77 | 69 | 63 | 83 | 106 | 117 | 131 |
| Total Assets | 27 | 87 | 89 | 91 | 88 | 81 | 77 | 100 | 127 | 141 | 155 |
Cash Flow
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | -4 | 1 | 8 | 1 | 2 | 7 | -3 | 8 | 10 | 9 |
| Investing | — | 0 | -5 | -2 | -2 | -2 | -3 | -4 | -7 | -5 | -3 |
| Financing | — | 4 | 4 | -6 | 1 | -1 | -3 | 8 | -2 | -4 | -4 |
| Net Cash Flow | — | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -1 | 0 | 2 |
| Free Cash Flow | — | -4 | 0 | 6 | -1 | 0 | 4 | -7 | 1 | 5 | 6 |
| CFO/EBITDA | — | -123 | 38 | 138 | 40 | 60 | 134 | -17 | 106 | 123 | 71 |
Ratios
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92 | 121 | 65 | 77 | 88 | 72 | 73 | 75 | 86 | 65 | 55 |
| Inventory Days | 66 | 67 | 42 | 65 | 47 | 78 | 60 | 57 | 65 | 59 | 70 |
| Days Payable | 142 | 177 | 85 | 124 | 74 | 93 | 87 | 85 | 112 | 97 | 78 |
| Cash Conversion Cycle | 16 | 11 | 23 | 18 | 61 | 56 | 46 | 48 | 38 | 26 | 47 |
| Working Capital Days | 3 | 14 | 14 | 15 | 20 | 28 | 25 | 36 | 31 | 22 | 24 |
| ROCE % | — | 31% | 34% | 24% | 14% | 11% | 12% | 16% | 13% | 13% | 20% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aristo Bio-Tech & Lifescience insights
57 extracted metrics + investor summaries across FY16–FY26.
Documents
Frequently Asked Questions about Aristo Bio-Tech & Lifescience
What does Aristo Bio-Tech & Lifescience Ltd do?
Where is Aristo Bio-Tech & Lifescience Ltd (ARISTO) listed?
Which sector does Aristo Bio-Tech & Lifescience Ltd belong to?
What is the market capitalisation of Aristo Bio-Tech & Lifescience Ltd?
What is the 52-week high and low of Aristo Bio-Tech & Lifescience Ltd?
Does Aristo Bio-Tech & Lifescience Ltd pay dividends?
What is the Return on Equity (ROE) of Aristo Bio-Tech & Lifescience Ltd?
Company Information
Incorporated in 2005, Aristo Bio-Tech and Lifescience Ltd manufactures and supplies pesticides and agrochemicals[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ARISTO.md for Aristo Bio-Tech & Lifescience Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.